Replies to post #130867 on NanoViricides Inc (NNVC)

[arvitar]

In any case, you may have noticed that NNVC is having a hell of a time scaling up. I suspect several PhDs are assigned to solving that problem.

I never bought that. There are process chemists with decades of experience in the pharma industry in scaling up difficult schemes. One pays an outside lab with such expertise to do that work. The cost in hiring such experts as full time employees, and spending the millions to install the infrastructure to support that capability in-house doesn't make sense for any startup pharma.

Tox requires methods for detecting the breakdown products of nanoviricides in tissues. I suspect more PhDs are working on that

Characterizing metabolites is done as part of the ADME work done by the same GLP certified labs doing the IND enabling studies. Again, it makes no sense for a startup to spend the millions for setting up that capability in house. It costs some tens of thousands of dollars to just pay a CRO with that expertise to do the work.

If NNVC has a single lead candidate as Seymour claims, there is no conceivable in-house work that could be done to further its development, where outside CRO's with the requisite expertise could do it faster and at a fraction of the cost.